Inatani Masaru, Iwao Keiichiro, Kawaji Takahiro, Hirano Yoshio, Ogura Yuichiro, Hirooka Kazuyuki, Shiraga Fumio, Nakanishi Yoriko, Yamamoto Hiroyuki, Negi Akira, Shimonagano Yuka, Sakamoto Taiji, Shima Chieko, Matsumura Miyo, Tanihara Hidenobu
Department of Ophthalmology and Visual Science, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan.
Am J Ophthalmol. 2008 Apr;145(4):676-681. doi: 10.1016/j.ajo.2007.12.010. Epub 2008 Feb 19.
To determine the risk factors for intraocular pressure (IOP) elevation after the injection of triamcinolone acetonide (TA).
Retrospective interventional case-control study.
Multicenter.
Four hundred and twenty-seven patients.
Intraocular pressure levels after TA treatment by the sub-Tenon capsule injection (STI; 12 mg, 20 mg, or 40 mg), intravitreal injection (IVI; 4 mg or 8 mg), or the combination of STI (20 mg) and IVI (4 mg), and IOP levels after two TA treatments.
Risk factors for IOP levels of 24 mm Hg or higher.
Younger age (hazards ratio [HR], 0.96/year; P < .0001), IVI (HR, 1.89/year; P < .0001), and higher baseline IOP (HR, 1.15/mm Hg; P = .003) were identified as risk factors. Dose dependency was shown in STI-treated eyes (HR, 1.07/mg; P = .0006), as well as after IVI (HR, 1.64/mg; P = .013). The combination of STI and IVI was a significant risk factor (HR, 2.27; P = .003) compared with STI alone. In eyes receiving two TA treatments, IVI (HR, 2.60; P = .010), higher IOP elevation after the first injection (HR, 1.18/mm Hg; P = .011), and increased dosage of STI (HR, 1.07/mm Hg; P = .033) were risk factors.
Younger age, higher baseline IOP, IVI, and increased TA dosage were associated with TA-induced IOP elevation. IOP elevation after repeated TA injection was frequently associated with eyes treated with IVI, high IOP elevation after the first injection, and high doses of STI.
确定注射曲安奈德（TA）后眼压（IOP）升高的危险因素。
回顾性干预性病例对照研究。
多中心。
427例患者。
经Tenon囊下注射（STI；12mg、20mg或40mg）、玻璃体内注射（IVI；4mg或8mg）或STI（20mg）与IVI（4mg）联合治疗后眼压水平，以及两次TA治疗后的眼压水平。
眼压水平达到或高于24mmHg的危险因素。
年龄较小（风险比[HR]，0.96/年；P <.0001）、玻璃体内注射（HR，1.89/年；P <.0001）和较高的基线眼压（HR，1.15/mmHg；P =.003）被确定为危险因素。在Tenon囊下注射治疗的眼中显示出剂量依赖性（HR，1.07/mg；P =.0006），玻璃体内注射后也是如此（HR，1.64/mg；P =.013）。与单独的Tenon囊下注射相比，Tenon囊下注射与玻璃体内注射联合是一个显著的危险因素（HR，2.27；P =.003）。在接受两次TA治疗的眼中，玻璃体内注射（HR，2.60；P =.010）、首次注射后较高的眼压升高（HR，1.18/mmHg；P =.011）和Tenon囊下注射剂量增加（HR，1.07/mmHg；P =.033）是危险因素。
年龄较小、基线眼压较高、玻璃体内注射以及TA剂量增加与TA诱导的眼压升高有关。重复TA注射后的眼压升高通常与接受玻璃体内注射治疗的眼睛、首次注射后眼压大幅升高以及高剂量的Tenon囊下注射有关。
